Immunoengineers are experts who apply principles of engineering to design and optimize immune-based therapies. They work at the intersection of immunology, biotechnology, and bioengineering, developing novel approaches to enhance the immune system's ability to fight diseases. These professionals focus on designing engineered immune cells, such as CAR T-cells, and developing immunotherapies that can more effectively target and destroy cancer cells, pathogens, or other harmful agents. Immunoengineers use cutting-edge technologies, including genetic engineering, synthetic biology, and nanotechnology, to improve immune responses, making treatments more precise and less toxic for patients.
Their work in cancer and infectious disease treatment, immunoengineers are advancing the field of vaccine development by designing immunization strategies that enhance immune memory and response. They are also exploring the use of immune modulation to treat autoimmune diseases and chronic conditions. Immunoengineering is a rapidly evolving field, with researchers constantly pushing the boundaries to create more effective, personalized therapies. Through their interdisciplinary expertise, immunoengineers are making a significant impact on the future of medicine, transforming the way we approach immune system manipulation for therapeutic purposes. Immunoengineers are shaping the future of healthcare by developing innovative immune-based therapies that offer more targeted and effective solutions. Their work continues to revolutionize treatments, offering hope for curing previously untreatable conditions.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States